Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalantercept in Recurrent or Metastatic SCCHN
NCT01458392Phase 2Completed
- Start
- Oct 2011
- Primary completion
- Jun 2015
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of dalantercept in squamous cell carcinoma of the head and neck (HNSCC). Started Oct 2011; status: completed.
02
Drugs
dalantercept
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT01458392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01458392.